comparison of the effect of Saffron and Duloxetine on pain and depression in Rheumatoid arthritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171106037265N1

Enrollment

Registered

2018-03-07

Start date

2017-12-21

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depression. Condition 2: Depression. Major depressive disorder, single episode, mild Major depressive disorder, single episode, moderate

Interventions

Intervention 1: Intervention group: the Duloxetine group will receive 30 mg capsules(Sobhan pharmaceutical company) in the first week and then 60 mg will be given in two divided doses.the duration of

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ACR criteria for RA pain intensity at least 40 according to VAS

Exclusion criteria

Exclusion criteria: current or previous treatment with duloxetin axis I psychological disorder except MDD other structural rheumatological disorder except RA inflammatory , infectious , autoimmune arthritis active suicidal thoughts

Design outcomes

Primary

Measure	Time frame
Pain in Rheumatoid arthritis. Timepoint: first, third, sixth weeks. Method of measurement: BPI Questionnaire.;Depression in Rheumatoid arthritis. Timepoint: first, third, sixth weeks. Method of measurement: Hamilton Depression Survey Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkbar Fardi

Zahedan University of Medical Sciences

akbarfardi58@gmail.com+98 54 3329 5715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026